home All News open_in_new Full Article

Pfizer’s Metsera acquisition to spur Chinese search for new weight drugs

American pharmaceutical giant Pfizer’s up to US$7.3 billion acquisition of next-generation weight loss drugs developer Metsera will encourage more research spending on innovative products in China but is unlikely to draw new players into the fray, according to analysts. The acquisition of the US company, together with other deals by global pharmaceutical firms, would encourage companies already developing obesity drugs – including those in China – to continue their investments, said the...


today 3 w. ago attach_file Events

attach_file Economics
attach_file Politics
attach_file Events
attach_file Politics
attach_file Events
attach_file Events
attach_file Events


ID: 2739981040
Add Watch Country

arrow_drop_down